This site is intended for healthcare professionals

Tepotinib is recommended by NICE to treat advanced non-small-cell lung cancer with METex14 skipping alterations in adults.- Merck KGaA

Read time: 1 mins
Published:15th Apr 2022

Why the committee made these recommendations ? Standard care for advanced METex14 skipping NSCLC is usually chemoimmunotherapy. People have different treatments depending on their PD-L1 tumour proportion score and whether they have squamous or non-squamous NSCLC. Clinical trial evidence suggests a clinical benefit for tepotinib. It has been indirectly compared with other treatments in 2 ways, but the results of both are uncertain. Tepotinib meets NICE’s criteria to be considered a life-extending drug at the end of life for people who have had previous treatment, but not for people who have not had previous treatment. For both groups, the cost-effectiveness estimates are within the range NICE normally considers an acceptable use of NHS resources. So, tepotinib is recommended.

Condition: NSCLC / MET
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.